Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery
Stress Urinary Incontinence, Surgical Incision, Pain Vulva
About this trial
This is an interventional treatment trial for Stress Urinary Incontinence
Eligibility Criteria
Inclusion Criteria: undergoing retropubic mid-urethral sling surgery (with concomitant anterior repair or urethrocele repair) English as first language Exclusion Criteria: patients undergoing concomitant posterior repair, vaginal vault suspension, or any other intra-peritoneal surgeries including hysterectomy NSAID use within 7 days of surgery steroid use within 10 days daily opioid use in the last 3 months long acting opioids within 3 days any opioids within 24h patients unable to consent for themselves patients allergic to meloxicam or bupivacaine pregnant or lactating patients
Sites / Locations
- Cincinnati Urogynecology AssociatesRecruiting
- Trihealth (Good Samaritan Hospital, Bethesda North Hospital)Recruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
bupivacaine-meloxicam
Standard of Care
All patients will receive a total of 20 cc lidocaine with epinephrine injection intra-operatively along the trocar path via the suprapubic incisions, as is standard practice to help with hydrodissection for the procedure. 3-4 cc of bupivacaine-meloxicam will be infiltrated into each suprapubic abdominal incision in the study group
All patients will receive a total of 20 cc lidocaine with epinephrine injection intra-operatively along the trocar path via the suprapubic incisions, as is standard practice to help with hydrodissection for the procedure.